Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Dividend

Can we ASSUME

in response to by
posted on Feb 08, 2007 09:44AM

Wondering now if the PubPat request was backed by ARM. Thought it might have made sense if they saw the potential for the existing requests for patent reexam pulled. As I understand it, the PubPat request would necessarily have to be different than the NEC and Toshiba's. Perhaps that is reason the PubPat request seemed so weak. But wouldn't it have been better to wait for the NEC/Toshiba requests to be yanked, and then PubPat could have used some/all of that amo. If that PubPat request was backed by ARM, they may have made a blunder. Any other thoughts.

Share
New Message
Please login to post a reply